PF-05231023 is primarily investigated for its potential therapeutic applications in metabolic disorders, particularly in the management of obesity and type 2 diabetes. It functions as a long-acting fibroblast growth factor 21 (FGF21) analog, which plays a key role in regulating glucose and lipid metabolism. By mimicking the action of FGF21, it enhances insulin sensitivity, promotes weight loss, and improves lipid profiles in preclinical studies. This makes it a promising candidate for addressing complications associated with metabolic syndrome. Ongoing research aims to evaluate its efficacy and safety in clinical trials, potentially offering a novel treatment option for patients with these chronic conditions.